JAPAN MEDICAL AFFAIRS SUMMIT





2024



Welcome Letter

Dear Esteemed Colleagues & Guests,

On behalf of the organizing committee, it is with great pleasure that we extend a warm welcome to attendees of the 2nd Annual Japan Medical Affairs Summit in Tokyo. This exciting event, co-organized by JAPhMed, PhRMA and MAPS, will focus on the major impact digital is having across Medical Affairs disciplines with this year's theme, "Digital Innovations in Medical Affairs: Transforming Patient Outcomes."

We are thrilled to host this prestigious event, bringing together industry leaders, medical professionals, and experts from around the globe who will share their expertise and perspectives on a wide range of topics, including Digital Transformation and the Role of Medical Affairs, Patient Centricity & Continuing Medical Education, How to Establish the MSL in Japan, Career Development and more. We have designed the program to feature informal and formal presentations, panels and a workshop to encourage open-dialogue, networking and knowledge-sharing.

We are confident that you will find this conference to be an invaluable opportunity to learn about the latest trends, insights, and best practices in Medical Affairs for you to help shape the future of healthcare in Japan.

We look forward to welcoming you in Tokyo!

Best regards,



Yasuyuki Katayama Medical Affairs Committee Chair PhRMA



Shinichi Nishiuma Vice Chairperson, Head of Medical Affairs Committee JAPhMed



Victoria Elegant President, APAC MAPS

Co-Organized By



PhRMA

Since the opening in 1987, PhRMA's Japan office has actively developed various activities on behalf of its member companies in Japan. We promote activities focused on direct dialogue with all concerned parties such as government officials, doctors and other medical staff, media parties and patient organizations. PhRMA cooperates with the Japan Pharmaceutical Federation, the Japan Pharmaceutical Industry Association and the European Pharmaceutical Federation to develop activities.



JAPhMed

JAPhMed has more than 50 years of history in developing "pharmaceutical medicine" in Japan which is defined as a medical specialty concerned with the discovery, development, evaluation, licensing and monitoring of medicines and the medical aspects of their marketing. Based on our mission: "To promote Pharmaceutical Medicine by enhancing the knowledge, expertise and skills of pharmaceutical professionals and physicians, thus leading to the availability and appropriate use of medicines for the benefit of patients and the society." JAPhMed operates as the Japanese affiliate of the International Federation of Associations of Pharmaceutical Physicians & Pharmaceutical Medicine (IFAPP).



MAPS

The Medical Affairs Professional Society (MAPS) is the premier non-profit global Medical Affairs organization FOR Medical Affairs professionals BY Medical Affairs professionals across all different levels of experience/specialty. Together with over 10,500 Medical Affairs members from 300+ companies globally, MAPS is transforming the Medical Affairs profession to increase its value to patients, HCPs, industry and society. MAPS transforms Medical Affairs organizations and Medical Affairs professionals globally by: speaking as the single voice of the Medical Affairs profession; defining the current and future practice of Medical Affairs; being the global community for Medical Affairs professionals; and leveraging collective thought leadership to train the next generation of Medical Affairs leaders.

Distinguished Advisory Board



Yasuyuki Katayama Associate Vice President Scientific Advisor & Medical Affairs Committee Chair MSD K.K. / PhRMA



Shinichi Nishiuma
Chief Medical Officer & Vice
Chairperson, Head of Medical
Affairs Committee
Aculys / JAPhMed



Victoria Elegant President, APAC MAPS



Takeshi (George) Imaoka
Associate Vice President-Medical
Diabetes Products & Clinical
Pharmacology, Medical Japan Drug
Development & Medical
Affairs & Medical Affairs Committee
Vice-Chair
Eli Lilly Japan K.K. / PhRMA



Michiko Tomiyasu Senior Manager, MSL Excellence, MO, Medical Affairs Division / MSL Training Curriculum Lead Alexion Pharma / JAPhMed



Toshifumi Suzuki
MSL / Medical Affairs
Committee Working Group 3,
Leader
MSD K.K. / PhRMA



Yi Piao
Director, Scientific Innovation /
Working Group 1 Leader, Medical
Affairs Committee
Gilead Sciences K.K. / PhRMA



Takahashi Kanemitsu
Scientific Communications /
Working Group 3, Medical Affairs
Committee
Amgen K.K. / PhRMA

Monday, April 22 - General Session

*Simultaneous Translation in Japanese/English will be provided for the entire General Session on April 22.

8:15 - 8:50 Registration, Networking & Exhibition Hall Open

8:50 - 9:00 Welcome Remarks

Shinichi Nishiuma
Vice Chairperson, Head of
Medical Affairs Committee
JAPhMed

Chief Medical Officer

Aculys

Yasuyuki Katayama Medical Affairs Committee Chair PhRMA Associate Vice President

Scientific Advisor **MSD K.K.**

Victoria Elegant APAC President MAPS

9:00 - 9:30 The Critical Impact in Medical Affairs of Cross Functional Alignment to Impact Patient Outcomes

Fireside Chat

Matthew Robson Corporate Officer, Chief Medical Officer Novartis Pharma K.K.

Leo Lee
President and Representative Director
Novartis Pharma K.K.

Monday, April 22 - General Session

*Simultaneous Translation in Japanese/English will be provided for the entire General Session on April 22.

9:30 - 10:30

The Impact of Digital on Medical Affairs

Keynote Panel

Moderator:

Victoria Elegant President, APAC

MAPS

Panelists:

Yasuyuki KatayamaMedical Affairs Committee Chair

PhRMA
Associate Vice President

Scientific Advisor MSD K.K.

Pauline Ng

Vice President, Head of Medical

Affairs Japan

Janssen Pharma K.K.

Shinichi Nishiuma

Vice Chairperson, Head of Medical Affairs Committee

JAPhMed

Chief Medical Officer

Aculys

Shuhei Fujita

Senior Vice President, Head of

Medical Affairs **Astellas Pharma**

Helen Lin

Corporate Officer, Medical Affairs Executive Medical Director

Amgen K.K.

10:30 - 11:00 Networking Break & Exhibits

Monday, April 22 - General Session

*Simultaneous Translation in Japanese/English will be provided for the entire General Session on April 22.

Digital Transformation and the Role of Medical Affairs

Session Moderator:

Takeshi (George) Imaoka

Associate Vice President-Medical Diabetes Products & Clinical Pharmacology, Medical Japan Drug Development & Medical Affairs & Medical Affairs Committee Vice-Chair Eli Lilly Japan K.K. / PhRMA

11:00 - 11:15 What's the Impact of Digital and AI on Medical Affairs? Best Practices from Digital Initiatives

Tadashi Umeda

Executive Director, Japan Medical Affairs Capabilities

MSD K.K.

11:15 - 11:30 What's the Impact of Digital and AI on Medical Affairs? Best Practices from Company Perspective

Akihiro Konishi

Associate Director of Medical Digital Solution, Medical Affairs Capabilities,

Japan Drug Development & Medical Affairs

Eli Lilly Japan K.K.

11:30 - 12:00 Voices from Around the World: Insights from US/EU/APAC Regions

Tamas Koncz

Chief Medical Officer International Developed Markets, ACCORD/GCAP

Pfizer

12:00 - 12:30 How Digital Thinking Enables Medical Strategy

Bora Erdemli
Principal
Vandana Garg (virtual)
Medical & Scientific Affa

Principal Medical & Scientific Affairs Lead, Southeast Asia & Taiwan

ZS Associates Haleon

Monday, April 22 - General Session

*Simultaneous Translation in Japanese/English will be provided for the entire General Session on April 22.

12:30 - 13:00 **Q&A and Panel Discussion**

Moderator:

Bora Erdemli
Principal
ZS Associates

Panelists:

Tadashi Umeda Executive Director, Japan Medical Affairs Capabilities MSD K.K.

Tamas Koncz
Chief Medical Officer International
Developed Markets, ACCORD/GCAP
Pfizer

13:00 - 14:00 Bento Box Lunch

Akihiro Konishi Associate Director of Medical Digital Solution Eli Lilly Japan K.K.

Monday, April 22 - General Session

*Simultaneous Translation in Japanese/English will be provided for the entire General Session on April 22.

Patient Centricity & Continuing Medical Education (CME)

Session Moderators:

Yasuyuki Katayama Associate Vice President Scientific Advisor & Medical Affairs Committee Chair MSD K.K. / PhRMA Toshifumi Suzuki
MSL / Medical Affairs Committee Working Group 3, Leader
MSD K.K. / PhRMA

14:00 - 14:30 Change From the Perspective of the Patient

Hiromi Todoroki Chairperson NPO Kibou-no-kai

14:30 - 15:00 Challenges of Continuing Medical Education (CME) in Japan

Tamio Teramoto

Academic Research Center (TARC) Specially Appointed Professor

Teikyo University

15:00 - 15:30 **Q&A and Panel Discussion**

Moderator:

Yasuyuki Katayama

Associate Vice President Scientific Advisor &

Medical Affairs Committee Chair

MSD K.K. / PhRMA

Panelists:

Hiromi Todoroki Chairperson

NPO Kibou-no-kai

Tamio Teramoto
Academic Research Center (TARC)
Specially Appointed Professor
Teikyo University

15:30 - 16:00 Networking Break & Exhibits

Monday, April 22 - General Session

*Simultaneous Translation in Japanese/English will be provided for the entire General Session on April 22.

How to Establish the MSL in Japan

Session Moderators:

Yasuyuki Katayama Associate Vice President Scientific Advisor & Medical Affairs Committee Chair MSD K.K. / PhRMA **Toshifumi Suzuki**MSL / Medical Affairs Committee Working Group 3, Leader **MSD K.K. / PhRMA**

16:00 - 16:20 Challenges From the Perspective of Pharmaceutical Industry

Akira Noguchi

Director of MSL, Medical Affairs Dept. Integrated Disease Care Division /

Vice Chairperson of Medical Affairs Expert Committee

Shionogi & Co. Ltd. / Japan Pharmaceutical Manufacturer's Association (JPMA)

16:40 - 17:00 Challenges and Suggestions From the Perspective of a Former MHLW Officer

Takamasa Horio

Partner

Mori Hamada & Matsumoto

17:00 - 17:30 Challenges and Suggestions From the Perspective of Academia

Katsunori Yamaura

Professor, Center for Social Pharmacy and Pharmaceutical Care Sciences, Division of Social Pharmacy

Keio University

16:20 - 16:40 Challenges From the Perspective of Thought Leader

Speaker To Be Announced Shortly

Monday, April 22 - General Session

*Simultaneous Translation in Japanese/English will be provided for the entire General Session on April 22.

17:30 - 18:25

Panel Discussion

Moderator:

Yasuyuki Katayama

Associate Vice President Scientific Advisor & Medical Affairs Committee Chair

MSD K.K. / PhRMA

Panelists:

Akira Noguchi

Director of MSL, Medical Affairs Dept. Integrated Disease Care Division / Vice Chairperson of Medical Affairs Expert Committee Shionogi & Co. Ltd. / JPMA

Takamasa Horio
Partner
Mori Hamada & Matsumoto

18:25 - 18:30 General Session Closing Remarks

Michiko Tomiyasu

Senior Manager, MSL Excellence, MO, Medical Affairs Division / MSL Training Curriculum Lead **Alexion Pharma / JAPhMed**

Katsunori Yamaura

Professor, Center for Social Pharmacy and Pharmaceutical Care Sciences, Division of Social Pharmacy

Keio University

18:30 - 19:30

Evening Cocktail Reception

We would be honored to have you join us at our Evening Cocktail Reception, which will take place directly at the meeting venue. After a long day of productive discussions, we look forward to opportunities to make valuable business connections. Over wine, beers, soft drinks and finger foods, you'll have the chance to meet with industry peers, chat with thought leaders, and expand your network. We can't wait to see you there!

Tuesday, April 23 - Career Development Workshop

*The Career Development Workshop on April 23 will be held in Japanese and translation to English WILL NOT be provided.

8:30 - 9:00

Career Development Workshop Registration

9:00-13:00

Workshop

Navigating Your Medical Affairs Career: A Workshop on Growth and Development

Are you looking to take your medical affairs career to the next level? This interactive workshop is designed to help you navigate the often complex landscape of professional development in the medical affairs field. Our expert speakers will guide you through the key stages of career growth, from understanding your strengths and opportunities to developing a personalized plan for success.

Moderators:

Yi Piao

Director, Scientific Innovation Lead / Working Group 1 Leader, Medical Affairs Committee Gilead Sciences K.K. / PhRMA

Yoichi Inoue Janssen K.K. / JAPhMed

Speakers:

Takahiro Katayama BMS

Tomoko Takami Senior Director, Head of Oncology Medical Affairs Gilead Sciences K.K.

Takashi Kanemitsu

Scientific Communication / Medical Affairs Committee Working Group 3 Amgen / PhRMA

Michiko Tomiyasu

Senior Manager, MSL Excellence, MO, Medical Affairs Division / MSL Training Curriculum Lead **Alexion Pharma / JAPhMed**

Makio Kamida
Director, Health Care Compliance
Janssen Pharmaceutical K.K.

Speaking Faculty



Shinichi Nishiuma
Chief Medical Officer & Vice
Chairperson, Head of Medical
Affairs Committee
Aculys / JAPhMed



Yasuyuki Katayama Associate Vice President Scientific Advisor & Medical Affairs Committee Chair MSD K.K. / PhRMA



Victoria Elegant APAC President MAPS



Takeshi (George) Imaoka
Associate Vice President-Medical
Diabetes Products & Clinical
Pharmacology, Medical Japan Drug
Development & Medical
Affairs & Medical Affairs Committee
Vice-Chair
Eli Lilly Japan K.K. / PhRMA



Helen Lin
Corporate Officer, Medical Affairs,
Executive Medical Director
Amgen K.K.



Michiko Tomiyasu Senior Manager, MSL Excellence, MO, Medical Affairs Division / MSL Training Curriculum Lead Alexion Pharma / JAPhMed



Heidi Anthoni Senior Director, Medical Affairs ASCA Business Division Daiichi-Sankyo



Jan van Overbeeke Partner McKinsey & Company



Toshifumi Suzuki
MSL / Medical Affairs Committee
Working Group 3, Leader
MSD K.K. / PhRMA



Tamas Koncz
Chief Medical Officer, International
Developed Markets, ACCORD/GCAP
Pfizer



Leo Lee
President and Representative
Director
Novartis Pharma K.K.





Matthew Robson
Corporate Officer, Chief Medical
Officer
Novartis Pharma K.K.



Pauline Ng Vice President, Head of Medical Affairs Japan Janssen Pharma K.K.



Bora Erdemli Principal ZS Associates

Speaking Faculty



Shuhei Fujita Senior Vice President, Head of Medical Affairs Astellas Pharma



Akihiro Konishi
Associate Director of Medical
Digital Solution
Eli Lilly Japan K.K.



Akira Noguchi
Director of MSL, Medical Affairs
Dept. Integrated Disease Care
Division / Vice Chairperson of
Medical Affairs Expert Committee
Shionogi & Co. Ltd. / JPMA



Takeshi (George) Imaoka
Associate Vice President-Medical
Diabetes Products & Clinical
Pharmacology, Medical Japan Drug
Development & Medical
Affairs & Medical Affairs Committee
Vice-Chair
Eli Lilly Japan K.K. / PhRMA



Helen Lin
Corporate Officer, Medical Affairs,
Executive Medical Director
Amgen K.K.



Michiko Tomiyasu Senior Manager, MSL Excellence, MO, Medical Affairs Division / MSL Training Curriculum Lead Alexion Pharma / JAPhMed

Tadashi Umeda Executive Director, Japan Medical Affairs Capabilities MSD K.K.

Takamasa Horio
Partner
Mori Hamada & Matsumoto

Katsunori Yamaura
Professor, Center for Social
Pharmacy and Pharmaceutical
Care Sciences, Division of Social
Pharmacy
Keio University

Hiromi Todoroki Chairperson NPO Kibou-no-kai





Makio Kamida
Director, Health Care Compliance
Janssen Pharmaceutical K.K.

Registration



	Early Bird	Regular
	(Ends March 1, 2024)	(Begins March 2, 2024)
JAPhMed, MAPS or PhRMA Member BioPharma Company Rate	\$125	\$175
Non-Member BioPharma Company Rate	\$200	\$250
Non-Member BioPharma Company Group Rate*	\$175	\$200
*3 or more attendees from the same company		
Non-BioPharma Company Rate	\$500	\$600
Academic / Hospital Rate	\$100	\$125
	<u> </u>	
Career Development Workshop Only (April 23) *Workshop in Japanese; En Single Rate	glish/Japanese translation N	NOT Provided \$100
	<u> </u>	
Single Rate	\$90	
Single Rate Main Session + Career Development Workshop (April 22 & 23)	\$90	\$100
Single Rate Main Session + Career Development Workshop (April 22 & 23) JAPhMed, MAPS or PhRMA Member BioPharma Company Rate	\$90 \$200	\$100 \$250
Single Rate Main Session + Career Development Workshop (April 22 & 23) JAPhMed, MAPS or PhRMA Member BioPharma Company Rate Non-Member BioPharma Company Rate	\$90 \$200 \$275	\$100 \$250 \$325
Single Rate Main Session + Career Development Workshop (April 22 & 23) JAPhMed, MAPS or PhRMA Member BioPharma Company Rate Non-Member BioPharma Company Rate Non-Member BioPharma Company Group Rate*	\$90 \$200 \$275	\$100 \$250 \$325

Register at medicalaffairs.org/japan2024

Venue & Information





Meeting Venue Information

Nihonbashi Life Science HUB

Address: 1-5-5, Nihonbashi-muromachi, Chuo-ku, Tokyo 103-0022

Japan

Phone: +81 3-6888-8080

Access by JR Line + Tokyo Metro

Tokyo Metro Ginza Line / Hanzomon Line

Directly connected to "Mituikoshimae" Station

JR Sobu Line

Directly connected to "Shin-nihonbashi" Station

JR Yamanote Line / Keihin-Tohoku Line / Chuo Line Rapid

9-minute walk from South Exit of "Kanda" Station

9-minute walk from Nihonbashi Exit of "Tokyo" Station

If you have any questions about Sponsorship, Exhibition or Attendance, please contact: jon.liong@lycheegroup.com